Ardelyx
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 267
- Market Cap
- $1.4B
- Website
- http://www.ardelyx.com
- Introduction
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 80
- Registration Number
- NCT02819687
Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 105
- Registration Number
- NCT02796131
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
- Conditions
- Constipation Predominant Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 312
- Registration Number
- NCT02727751
- Locations
- πΊπΈ
Ardelyx Clinical Site, Miami, Florida, United States
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
- Conditions
- Constipation Predominant Irritable Bowel Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 593
- Registration Number
- NCT02686138
- Locations
- πΊπΈ
Ardelyx Investigative Site 257, Dothan, Alabama, United States
πΊπΈArdelyx Investigative Site 200, Foley, Alabama, United States
πΊπΈArdelyx Investigative Site 103, Huntsville, Alabama, United States
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 219
- Registration Number
- NCT02675998
- Locations
- πΊπΈ
Ardelyx Investigative Site 429, Huntsville, Alabama, United States
πΊπΈArdelyx Investigative Site 425, Riverside, California, United States
πΊπΈArdelyx Clinical Site 403, Denver, Colorado, United States
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
- Conditions
- Constipation Predominant Irritable Bowel Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 606
- Registration Number
- NCT02621892
- Locations
- πΊπΈ
Ardelyx Investigative Site 149, Birmingham, Alabama, United States
πΊπΈArdelyx Investigative Site 114, Birmingham, Alabama, United States
πΊπΈArdelyx Investigative Site 103, Huntsville, Alabama, United States
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 16
- Registration Number
- NCT02346890
- Locations
- πΊπΈ
Healthcare Discoveries, LLC, San Antonio, Texas, United States
A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 18
- Registration Number
- NCT02249936
- Locations
- πΊπΈ
ICON Development Solutions, Omaha, Nebraska, United States
D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects
- Conditions
- Healthy Volunteers Food Interaction Study
- Interventions
- Drug: AZD1722 salt tabletDrug: AZD1722 free base tabletDrug: AZD1722 free base tablet + Omeprazole
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 37
- Registration Number
- NCT02226783
- Locations
- πΊπΈ
Research Site, Overland Park, Kansas, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 83
- Registration Number
- NCT02176252
- Locations
- πΊπΈ
WCCT Global, Cypress, California, United States